Moving Towards Induced Pluripotent Stem Cell-based Therapies with Artificial Intelligence and Machine Learning

Stem Cell Rev Rep. 2022 Feb;18(2):559-569. doi: 10.1007/s12015-021-10302-y. Epub 2021 Nov 29.

Abstract

The advent of induced pluripotent stem cell (iPSC) technology, which allows to transform one cell type into another, holds the promise to produce therapeutic cells and organs on demand. Realization of this objective is contingent on the ability to demonstrate quality and safety of the cellular product for its intended use. Bottlenecks and backlogs to the clinical use of iPSCs have been fully outlined and a need has emerged for safer and standardized protocols to trigger cell reprogramming and functional differentiation. Amidst great challenges, in particular associated with lengthy culture time and laborious cell characterization, a demand for faster and more accurate methods for the validation of cell identity and function at different stages of the iPSC manufacturing process has risen. Artificial intelligence-based methods are proving helpful for these complex tasks and might revolutionize the way iPSCs are managed to create surrogate cells and organs. Here, we briefly review recent progress in artificial intelligence approaches for evaluation of iPSCs and their derivatives in experimental studies.

Keywords: Artificial intelligence; Deep learning; Induced pluripotent stem cells; Machine learning; Quality control; Regenerative medicine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Artificial Intelligence
  • Cellular Reprogramming
  • Induced Pluripotent Stem Cells*
  • Machine Learning